Novo Nordisk will join lawsuit over end of semaglutide shortage
Novo Nordisk got the green light to join a lawsuit by compounders against the FDA after the agency deemed that the Danish pharma's blockbuster weight loss drug was no longer in shortage. Judge Mark...
View ArticleJudge grants new nationwide block on NIH payment cuts
A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. Judge Angel ...
View ArticleITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera
ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal data...
View ArticleNovo Nordisk looks into starting GLP-1 drug trials for addiction
Novo Nordisk is considering investigating its GLP-1 therapies in the treatment of addictions, mirroring similar comments made by its major incretin rival Eli Lilly. Novo is already studying its GLP-1...
View ArticleNo news is good news? Merck KGaA quiet on potential SpringWorks takeover
Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its potential buyout of SpringWorks Therapeutics. But the German pharma was...
View ArticleMakary hearing updates: Trump FDA nominee faces Senate
Johns Hopkins surgeon Marty Makary, President Donald Trump's pick to lead the FDA, emerged from his Senate confirmation hearing relatively unscathed. During the less than two-hour hearing, Makary vowed...
View ArticleDenali stops some work on ALS drug after analysis showed no impact on key...
Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for FDA approval after a failed topline readout earlier this year. The company is...
View ArticleMerck KGaA says earlier moves to localize manufacturing help ease Trump...
Merck KGaA flagged that it might get hit by President Donald Trump’s tariffs against China, but CEO Belén Garijo said this is likely to be “manageable” due to its earlier execution of regionalizing its...
View ArticleCorrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on...
Plus, news about Tris Pharma and ARS Pharmaceuticals: Merck KGaA’s lupus drug yields mixed data in mid-stage trial: The drugmaker’s TLR7/8 inhibitor, called enpatoran, missed one of two Phase 2 primary...
View ArticleLuxa's stem cell therapy for dry AMD shows early promise
Luxa Biotechnology said Thursday that its stem cell therapy helped improve vision in a handful of people with a common form of an age-related eye condition. In its lowest dose cohort, the Phase 1/2a...
View ArticleNovo Nordisk’s rare disease ‘company within a company’ has an open goal in...
Novo Nordisk is known for making therapies for some of the world’s most prevalent conditions, but it's also working on candidates for some of the least common. Though the company’s rare disease unit is...
View ArticleLongtime biotech investor Frazier Life Sciences is raising its latest venture...
Frazier Life Sciences, a decades-old biotech investor, is raising another heap of dry powder to create and invest in startups, according to publicly available documents from one of its investors. The...
View ArticleCordenPharma’s €100M investment top-up; Cytiva to lay off 85 staffers
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. CordenPharma is investing another €100 million ($108 million) into...
View ArticleHealthcare is bullish on AI
It’s only been about two years since healthcare really started adopting generative AI. Now, it’s no longer just demos testing out transcription tools. Timed to the HIMSS conference, Microsoft, Google ...
View ArticleModerna stands by its Covid vaccine patents after PTAB decision
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over, even after a decision by an administrative tribunal that invalidated two of its Covid-19 vaccine-related patents. The...
View ArticleWalgreens to go private in $10B deal
Walgreens is entering a new chapter as it agrees to sell itself to a private equity firm, ending its rocky run as a publicly traded company. New York-based Sycamore Partners is acquiring the retail...
View ArticleJ&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly...
Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental and new type of major depressive disorder drug, following "insufficient efficacy," the pharma giant disclosed late...
View ArticleTune’s CEO search ends as John McHutchison takes top spot; More from Pfizer’s...
John McHutchison started Monday as CEO and chairman of Tune Therapeutics, after sitting on the company’s board for two years. One message he wants to make clear: “We’re not a gene ...
View ArticleRoche launches new research center with Harvard in Boston area
Roche announced a new research hub on Friday in partnership with Harvard that it hopes will accelerate efforts in disease biology, engineering and AI. The hub will be called the Roche Genentech...
View ArticleCytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis
Plus, news about Atea Pharmaceuticals: CytomX, Amgen stop work on T cell engager: The partners decided to end development of an EGFR-targeting T cell engager based on “clinical observations to date ...
View Article